Ubiquitin C-Terminal Hydrolase L5 (UCHL5) Accelerates the Growth of Endometrial Cancer via Activating the Wnt/β-Catenin Signaling Pathway

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

(2019) Stephanie M de Boer et al.   LANCET ONCOLOGY

CTHRC1 overexpression promotes ectopic endometrial stromal cell proliferation, migration and invasion via activation of the Wnt/β-catenin pathway

(2019) Yifei Lv et al.   REPRODUCTIVE BIOMEDICINE ONLINE

PPARα ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis

(2019) Lujin Wu et al.   BMC CANCER

LncRNA AC007271.3 promotes cell proliferation, invasion, migration and inhibits cell apoptosis of OSCC via the Wnt/β-catenin signaling pathway

(2019) Ting-ru Shao et al.   LIFE SCIENCES

Positive cytoplasmic UCHL5 tumor expression in gastric cancer is linked to improved prognosis

(2018) Leena Arpalahti et al.   PLoS One

Investigations on the mechanism of progesterone in inhibiting endometrial cancer cell cycle and viability via regulation of long noncoding RNA NEAT1/microRNA-146b-5p mediated Wnt/β-catenin signaling

(2018) Xiaohui Huang et al.   IUBMB LIFE

Deubiquitylating enzymes and drug discovery: emerging opportunities

(2017) Jeanine A. Harrigan et al.   NATURE REVIEWS DRUG DISCOVERY

Nuclear ubiquitin C-terminal hydrolase L5 expression associates with increased patient survival in pancreatic ductal adenocarcinoma

(2017) Leena Arpalahti et al.   TUMOR BIOLOGY

Addressing the Role of Obesity in Endometrial Cancer Risk, Prevention, and Treatment

(2016) Michaela A. Onstad et al.   JOURNAL OF CLINICAL ONCOLOGY

Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells

(2016) A Paulus et al.   Blood Cancer Journal

Proteasome inhibitors

(2015) Beverly A. Teicher et al.   BIOCHEMICAL PHARMACOLOGY

Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?

(2015) Karthik Selvaraju et al.   DRUG RESISTANCE UPDATES

Structural Plasticity Allows UCH37 to Be Primed by RPN13 or Locked Down by INO80G

(2015) Xiang Chen et al.   MOLECULAR CELL

Structural Basis for the Activation and Inhibition of the UCH37 Deubiquitylase

(2015) Ryan T. VanderLinden et al.   MOLECULAR CELL

Molecular Pathways: Translational Potential of Deubiquitinases as Drug Targets

(2014) P. D'Arcy et al.   CLINICAL CANCER RESEARCH

High expression of UCH37 is significantly associated with poor prognosis in human epithelial ovarian cancer

(2014) Lin Wang et al.   TUMOR BIOLOGY

Mechanism of the Rpn13-induced activation of Uch37

(2014) Lianying Jiao et al.   Protein & Cell

Induction of Tumor Cell Apoptosis by a Proteasome Deubiquitinase Inhibitor Is Associated with Oxidative Stress

(2013) Slavica Brnjic et al.   ANTIOXIDANTS & REDOX SIGNALING

Power and Promise of Ubiquitin Carboxyl-terminal Hydrolase 37 as a Target of Cancer Therapy

(2013) Yan-Jie Chen et al.   Asian Pacific Journal of Cancer Prevention

Regulation of deubiquitinase proteolytic activity

(2013) Oscar W Huang et al.   CURRENT OPINION IN STRUCTURAL BIOLOGY

Wnt/β-Catenin Signaling and Disease

(2012) Hans Clevers et al.   CELL

Expression and Clinical Significance of UCH37 in Human Esophageal Squamous Cell Carcinoma

(2012) Yanjie Chen et al.   DIGESTIVE DISEASES AND SCIENCES

Proteasome deubiquitinases as novel targets for cancer therapy

(2012) Pádraig D’Arcy et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Regulators of the Proteasome Pathway, Uch37 and Rpn13, Play Distinct Roles in Mouse Development

(2010) Amin Al-Shami et al.   PLoS One

Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases

(2009) Bryan T. MacDonald et al.   DEVELOPMENTAL CELL

New aspects of adjuvant therapy in endometrial cancer: Current standards and future directions

(2008) Jalid Sehouli et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY